$TPST (Tempest Therapeutics) — 8-K: Tempest Exercises Option to License Senlang CD7-Targeted In Vivo CAR-T Platform

Tempest Therapeutics exercised its option with Hebei Senlang Biotechnology for an exclusive license to develop and commercialize the CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates worldwide, excluding China. The lead program, TPST-4903, a BCMA/GPRC5D dual-targeting candidate, has been evaluated in 13 patients with relapsed or refractory multiple myeloma in the DELIVER-1 Phase 1 dose-escalation study, including patients with extramedullary disease and prior BCMA-targeted CAR-T exposure. Tempest characterized preliminary observations of clinical activity and tolerability as encouraging, supporting further evaluation, with detailed results planned for presentation at a major scientific conference. The license adds a clinical-stage lentiviral platform alongside Tempest's existing lipid nanoparticle delivery platform.

Tempest Therapeutics exercised its option with Hebei Senlang Biotechnology for an exclusive license to develop and commercialize the CD7-targeted lentiviral vector platform and associated in vivo CAR-